Technical Data
EphB3, NT (Ephrin Type-B receptor 3, Tyrosine-protein Kinase Receptor HEK-2, EPH-like Kinase 2, EK2, Tyrosine-protein Kinase TYRO6, ETK2, HEK2, TYRO6)
Ephrin receptors and their ligands, the ephrins, mediate numerous developmental processes, particularly in the nervous system. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. EphB3, a member of the Tyr family of protein kinases, is a receptor for members of the ephrin-B family; it binds to both ephrin-B1 and -B2. Expression of this Type I membrane protein is ubiquitous. The protein contains putative domains for 2 fibronectin type III and 1 sterile alpha motif (SAM).

Suitable for use in ELISA, Western Blot, and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
ELISA: 1:1,000
Western Blot: 1:100-1:500
Immunohistochemistry: 1:50-1:100
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
200ul-20CBlue IceHumanRabbit
As reported
Synthetic peptide selected from the N-terminal region of human EphB3 (KLH).
Purified by Protein G affinity chromatography.
Supplied as a liquid in PBS, 0.09% sodium azide.
Recognizes human EphB3.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Bohme, B., et al., Oncogene 8(10):2857-2862 (1993).